MRUS - メルス (Merus N.V.)

MRUSのニュース

   Merus NV (MRUS) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 23:15:05 Zacks Investment Research
Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO  2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.
   Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates  2019/11/12 23:15:09 Zacks Investment Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
   Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates  2019/08/19 21:15:07 Zacks Investment Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Merus NV (MRUS) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 23:15:05 Zacks Investment Research
Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO  2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.
   Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates  2019/11/12 23:15:09 Zacks Investment Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
   Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates  2019/08/19 21:15:07 Zacks Investment Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Merus NV (MRUS) Reports Q1 Loss, Misses Revenue Estimates  2020/05/11 23:15:05 Zacks Investment Research
Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO  2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.
   Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates  2019/11/12 23:15:09 Zacks Investment Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
   Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates  2019/08/19 21:15:07 Zacks Investment Research
Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

calendar